Table 3 Comparison of HCCs showing local progression and no local progression, in nodules classified with a complete response
Local progression N = 25 | No local progression N = 21 | p value* | |
|---|---|---|---|
Serum AFP level (μg /L) ± SD | 37 ± 18 | 122 ± 72 | 0.40 |
HCC size (mm) ± SD | 23 ± 7 | 22.6 ± 12 | 0.78 |
HCC location | |||
- Right lobe | 20 (80%) | 14 (66%) | 0.49 |
- Left Lobe | 5 (20%) | 7 (33%) | |
Capsule Appearance | 6 (24%) | 7 (33%) | 0.70 |
CBCT guidance | 15 (60%) | 10 (48%) | 0.82 |
Selective cTACE Treatment | 18 (72%) | 15 (71%) | 0.77 |
Mean Delivered Dose (mg) ± SD | 35 ± 17 | 48 ± 23 | 0.03 |
Presence of gas on follow-up CT | 1 (4%) | 0 (0%) | 0.93 |
Embolization Agent | |||
- Gelitaspon | 23 (92%) | 15 (71%) | 0.11 |
- PVA particles | 0 (0%) | 3 (14%) | |
- No embolization | 2 (8%) | 3 (14%) | |